Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction

OBJECTIVES: To investigate the acute effect of phosphodiesterase type 5 (PDE5) inhibitor on erectile dysfunction by evaluating serum oxidative status and prolidase activity. METHODS: Serum samples of 36 patients with erectile dysfunction and 30 control cases were analyzed for total antioxidant statu...

Full description

Bibliographic Details
Main Authors: Murat Savas, Ercan Yeni, Ayhan Verit, Mehmet Gulum, Nurten Aksoy, Halil Ciftci, Hakim Celik, Adem Altunkol, Halil Oncel
Format: Article
Language:English
Published: Faculdade de Medicina / USP 2010-01-01
Series:Clinics
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322010001200014
id doaj-22c7a326e88148dcb931002e3a644ee9
record_format Article
spelling doaj-22c7a326e88148dcb931002e3a644ee92020-11-24T23:57:21ZengFaculdade de Medicina / USPClinics1807-59321980-53222010-01-0165121311131410.1590/S1807-59322010001200014Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunctionMurat SavasErcan YeniAyhan VeritMehmet GulumNurten AksoyHalil CiftciHakim CelikAdem AltunkolHalil OncelOBJECTIVES: To investigate the acute effect of phosphodiesterase type 5 (PDE5) inhibitor on erectile dysfunction by evaluating serum oxidative status and prolidase activity. METHODS: Serum samples of 36 patients with erectile dysfunction and 30 control cases were analyzed for total antioxidant status, total oxidant status, and prolidase activity, before and after the administration of tadalafil citrate. RESULTS: Before and after tadalafil citrate administration, serum total antioxidant status, total oxidant status, and prolidase were 1.1+0.0 vs. 1.6 + 0.0 umol H2O2 Eq/L, 10.3+1.1 vs. 6.9 + 1.2 umol H2O2 Eq/L, and 236.4+19.5 vs. 228.2 + 19.2 U/L, respectively (p<0.0001 for all). CONCLUSIONS: Evaluation of serum oxidative status and prolidase activity confirmed the beneficial acute effects of PDE5 inhibitor in patients with erectile dysfunction.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322010001200014Phosphodiesterase type 5 inhibitorsTadalafil citrateTotal antioxidant statusTotal oxidant statusProlidase
collection DOAJ
language English
format Article
sources DOAJ
author Murat Savas
Ercan Yeni
Ayhan Verit
Mehmet Gulum
Nurten Aksoy
Halil Ciftci
Hakim Celik
Adem Altunkol
Halil Oncel
spellingShingle Murat Savas
Ercan Yeni
Ayhan Verit
Mehmet Gulum
Nurten Aksoy
Halil Ciftci
Hakim Celik
Adem Altunkol
Halil Oncel
Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
Clinics
Phosphodiesterase type 5 inhibitors
Tadalafil citrate
Total antioxidant status
Total oxidant status
Prolidase
author_facet Murat Savas
Ercan Yeni
Ayhan Verit
Mehmet Gulum
Nurten Aksoy
Halil Ciftci
Hakim Celik
Adem Altunkol
Halil Oncel
author_sort Murat Savas
title Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
title_short Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
title_full Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
title_fullStr Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
title_full_unstemmed Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
title_sort acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
publisher Faculdade de Medicina / USP
series Clinics
issn 1807-5932
1980-5322
publishDate 2010-01-01
description OBJECTIVES: To investigate the acute effect of phosphodiesterase type 5 (PDE5) inhibitor on erectile dysfunction by evaluating serum oxidative status and prolidase activity. METHODS: Serum samples of 36 patients with erectile dysfunction and 30 control cases were analyzed for total antioxidant status, total oxidant status, and prolidase activity, before and after the administration of tadalafil citrate. RESULTS: Before and after tadalafil citrate administration, serum total antioxidant status, total oxidant status, and prolidase were 1.1+0.0 vs. 1.6 + 0.0 umol H2O2 Eq/L, 10.3+1.1 vs. 6.9 + 1.2 umol H2O2 Eq/L, and 236.4+19.5 vs. 228.2 + 19.2 U/L, respectively (p<0.0001 for all). CONCLUSIONS: Evaluation of serum oxidative status and prolidase activity confirmed the beneficial acute effects of PDE5 inhibitor in patients with erectile dysfunction.
topic Phosphodiesterase type 5 inhibitors
Tadalafil citrate
Total antioxidant status
Total oxidant status
Prolidase
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322010001200014
work_keys_str_mv AT muratsavas acuteeffectofphosphodiesterasetype5inhibitoronserumoxidativestatusandprolidaseactivitiesinmenwitherectiledysfunction
AT ercanyeni acuteeffectofphosphodiesterasetype5inhibitoronserumoxidativestatusandprolidaseactivitiesinmenwitherectiledysfunction
AT ayhanverit acuteeffectofphosphodiesterasetype5inhibitoronserumoxidativestatusandprolidaseactivitiesinmenwitherectiledysfunction
AT mehmetgulum acuteeffectofphosphodiesterasetype5inhibitoronserumoxidativestatusandprolidaseactivitiesinmenwitherectiledysfunction
AT nurtenaksoy acuteeffectofphosphodiesterasetype5inhibitoronserumoxidativestatusandprolidaseactivitiesinmenwitherectiledysfunction
AT halilciftci acuteeffectofphosphodiesterasetype5inhibitoronserumoxidativestatusandprolidaseactivitiesinmenwitherectiledysfunction
AT hakimcelik acuteeffectofphosphodiesterasetype5inhibitoronserumoxidativestatusandprolidaseactivitiesinmenwitherectiledysfunction
AT ademaltunkol acuteeffectofphosphodiesterasetype5inhibitoronserumoxidativestatusandprolidaseactivitiesinmenwitherectiledysfunction
AT haliloncel acuteeffectofphosphodiesterasetype5inhibitoronserumoxidativestatusandprolidaseactivitiesinmenwitherectiledysfunction
_version_ 1725454385156194304